Overexpression of Smac/DIABLO in Hep-2 cell line: possible role in potentiating the sensitivity of chemotherapeutic drugs

Sumei Lu1, Wei Xu2, Zhaomin Fan2, Wenwen Liu1, Jianfeng Li1, and Haibo Wang1,2

1Institute of Eye and ENT, Provincial Hospital affiliated to Shandong University, Jinan; 2Department of Otolaryngology-Head and Neck Surgery, Provincial Hospital affiliated to Shandong University, Jinan, PR China. Sumei Lu and Wei Xu contributed equally to this work

ABSTRACT

Aims and background. The major obstacles for tumor chemotherapy are drug resistance and/or adverse effects on the host. In the present study we investigated the role of the second mitochondria-derived activator of caspase (Smac/DIABLO) in the action of cisplatin (DDP), 5-fluorouracil (5-FU), and the combination of both in Hep-2 cells.

Methods and study design. Hep-2 laryngeal carcinoma cells exposed to DDP, 5-FU and the combination of both were investigated. Cell viability was determined by MTT assay. Apoptosis was measured by Ho.33342 and PI double staining and flow cytometry. The expression of Smac/DIABLO at the mRNA and protein level was assayed by RT-PCR and Western blotting.

Results. DDP, 5-FU and the combination of both drugs reduced the cell survival rates in a concentration- and time-dependent manner. The drug combination not only exerted a stronger inhibitory effect, but also at a lower concentration compared with the single drugs. Apoptosis was concomitant in a caspase-dependent manner. The expression of Smac/DIABLO increased significantly at both mRNA and protein levels after cell exposure to the combination compared with single drugs.

Conclusions. Smac/DIABLO plays a pivotal role in attaining a synergistic effect in Hep-2 cells in response to this combined strategy. Free full text available at www.tumorionline.it

Key words: Smac/DIABLO, Hep-2 cells, chemotherapy, synergistic effect.

Correspondence to: Jianfeng Li or Haibo Wang, Institute of Eye and ENT, Provincial Hospital affiliated to Shandong University, Jinan, 25002, PR China.
Tel +86-531-85187583; fax +86-531-85187584; e-mail lijianfeng@hotmail.com or wanghb7585@hotmail.com

Received June 23, 2009; accepted November 17, 2009.